Calculators, Algorithms, Drug Interaction CheckersTools
Back To Search Results

Pregabalin

Author: Aaron L. Cross Author: Omar Viswanath Editor: Andrew L. Sherman Updated: 5/2/2024 3:17:04 AM

Indications

Pregabalin was approved by the United States Food and Drug Administration (FDA) in 2004. Pregabalin is utilized for neuropathic pain and seizures.

FDA-Approved Indications

  • Neuropathic pain associated with spinal cord injury [1]
  • Neuropathic pain associated with diabetic peripheral neuropathy [2]
  • Neuropathic pain originating from postherpetic neuralgia [3]
  • Adjunctive treatment for partial-onset seizures in adults with epilepsy [4]
  • Treatment of fibromyalgia [5]

European League Against Rheumatism (EULAR) guidelines note that pharmacological therapies should be considered for individuals experiencing severe pain or sleep disturbance. Pregabalin could be most appropriate when addressing both severe pain and sleep disturbance concurrently.[6]

Off-Label Uses

  • Generalized anxiety disorder [7]
  • Social anxiety disorder [8]
  • Insomnia [9]
  • Chronic pain conditions [10]
  • Uremic pruritus [11][12]
  • Chronic cough [13]
  • Restless leg syndrome [14][15]
  • Complex regional pain syndrome [16]
  • Prophylaxis of migraine [17]
  • Trigeminal neuralgia [18]

There is significant controversy regarding the efficacy of pregabalin for the off-label indications. Therefore, clinicians should carefully monitor patients for therapeutic success while monitoring adverse drug reactions.

Mechanism of Action

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care

Mechanism of Action

Pregabalin is structurally analogous to the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Pregabalin has been altered as a lipophilic formulation to enhance diffusion across the blood-brain barrier. However, the drug does not directly bind to GABA-A or GABA-B receptors. In preclinical studies, pregabalin binds to presynaptic voltage-gated calcium channels (VGCC) at the α-2-δ subunit in the central nervous system. The binding of the α-2-δ subunit reduces the depolarization-induced calcium influx into neurons and decreases the release of excitatory neurotransmitters. This action may account for the analgesic and anticonvulsant effects of pregabalin. Pregabalin has no known activity at serotonin, opiate sodium channels, or receptors and does not modify cyclooxygenase activity.[19]

Pharmacokinetics

Absorption: Pregabalin is absorbed in the small intestine and proximal colon in a linear and dose-proportional fashion. However, differences have been noted between pregabalin controlled-release and immediate-release formulations. Pregabalin controlled release (CR) achieves peak plasma concentrations within 8.0 hours (range: 5.0–12.0), contrasting with the more rapid attainment of peak concentration seen with immediate-release pregabalin, typically occurring at 0.7 hours (range: 0.7–1.5). 

Distribution: Pregabalin's apparent volume of distribution is approximately 0.5 L/kg. Pregabalin does not bind to plasma proteins.[20] Pregabalin readily crosses the blood-brain barrier.

Metabolism: Pregabalin does not induce or inhibit liver enzymes such as the cytochrome P450 system.[21]

Excretion: Pregabalin is primarily eliminated from the systemic circulation via renal excretion as an unchanged drug. In normal renal function, the mean elimination half-life of pregabalin is 6.3 hours. Pregabalin elimination is closely linked to creatinine clearance and is approximately proportional to creatinine clearance.

Administration

Available Dosage Forms and Strengths 

Pregabalin is offered in capsule form in strengths ranging from 25 to 300 mg, including 25, 50, 75, 100, 150, 200, 225, and 300 mg. Additionally, it is available as an oral solution at a concentration of 20 mg/mL. Extended-release tablets are also available in strengths of 82.5 mg, 165 mg, and 330 mg. Researchers have examined pregabalin at dosages up to 600 mg/d. However, they did not find 600 mg daily to provide significant additional benefit, and it was less well tolerated due to adverse effects. When discontinuing pregabalin, the recommendation is to taper the drug gradually over 1 week. In patients with seizure disorders, pregabalin should be withdrawn gradually to minimize the risk of increased seizure.

Adult Dosage

  • Management of neuropathic pain associated with diabetic peripheral neuropathy: The recommended maximum therapeutic dosage is 300 mg/d. The suggested starting dosage is 50 mg 3 times daily. The dosage can increase to 300 mg/d within 1 week of starting treatment.[22]
  • Management of neuropathic pain associated with spinal cord injury: The recommended therapeutic dosage is 150 mg to 600 mg daily. The recommended starting dosage is 75 mg twice daily. The dosage may be increased to 150 mg twice daily within 1 week of initiating treatment. Patients with suboptimal pain relief following 2 to 3 weeks of treatment with 150 mg twice daily may be increased up to 300 mg twice daily. In spinal cord injury, pain improvement can be seen as early as 1 week after initiating treatment. However, to evaluate the efficacy of pregabalin, it is recommended that the medication be tried for 4 to 6 weeks if the patient tolerates it.[23]
  • Management of postherpetic neuralgia: The recommended therapeutic dosage is 150 mg to 300 mg daily, divided into dosing twice or thrice daily. The recommended starting dosage is 75 mg twice daily or 50 mg thrice daily. The dosage can be increased to 300 mg daily within 1 week of starting treatment. After 2 to 4 weeks of treatment with 300 mg daily, patients with suboptimal pain relief can be increased to 600 mg, divided into twice daily or thrice daily. 
  • Management of fibromyalgia: The recommended therapeutic dosage is 300 mg to 450 mg daily. The recommended initial dosage is 150 mg/d, divided into twice-daily doses. The dosage can be increased to 300 mg daily within 1 week of starting treatment. Patients with suboptimal pain relief on 300 mg daily may further increase to 450 mg daily, divided into twice-daily dosing.
  • Adjunctive therapy for adults with partial onset seizures: Pregabalin is FDA-approved only as an adjunctive for treating partial-onset seizures. The effective dosage is 150 mg to 600 mg daily, divided twice or thrice-daily dosing. The suggested starting dosage is no greater than 150 mg daily, and the total dosage can increase to 600 mg daily. 
  • Cough and chronic refractory: Pregabalin is off-label used in cough and chronic refractory conditions. The initial dosage is 75 mg daily, which may increase by 75 mg during the first week of treatment. The maximum dosage can be up to 300 mg daily, divided thrice per dosing.[24]
  • Generalized anxiety disorder: Pregabalin is also off-label used in generalized anxiety disorder. The initial dosage is 75 mg daily, which may increase by 75 mg during the first week of treatment. The maximum dosage can be up to 300 mg thrice daily.[25]
  • Chronic pruritus: Pregabalin is also off-label and used as a preferred treatment in patients with pruritus resistance. The initial dosage is 75 mg twice daily, which may increase by 150 mg to 300 mg twice or thrice daily. The dosage of pregabalin can be increased up to 600 mg daily in oncology patient populations.[26]
  • Restless legs syndrome: Another off-label use of pregabalin is restless legs syndrome. The initial dosage is 50 to 75 mg daily before bedtime, which may increase by 75 to 150 mg weekly. The usual therapeutic dosage is up to 150 mg to 450 mg daily, based on the effectiveness and tolerability of therapy.[27]
  • Social anxiety disorder: Pregabalin is off-label used as mono or adjuvant therapy in social anxiety disorder, cough, and chronic refractory conditions. The initial dosage is 100 mg thrice daily, which may increase by 150 mg daily over 1 week. This dosage may increase to 600 mg daily based on response and tolerability.[28]

Specific Patient Population

Renal impairment: Pregabalin is primarily eliminated by renal excretion. Adjust the pregabalin dose in patients with impaired renal function. According to prescription drug manufacturers, the following are recommendations on dose reductions for patients with reduced creatinine clearance and those undergoing hemodialysis.

  • CrCl ≥60 mL/min: no dose modification is recommended
  • CrCl 30 to 60 mL/min: 50% dose of recommended daily dose
  • CrCl 15 to 30 mL/min: 25% dose of recommended daily dose
  • CrCl ≤15 mL/min: 16% to 8% dose of recommended daily dose

A supplementary dosage of approximately an additional 25 mg of the recommended daily dose following hemodialysis is recommended.

Hepatic impairment: Although not explicitly studied, because pregabalin is not protein-bound, it is unlikely that patients with hepatic impairment require dosing modifications.

Pregnancy considerations: Clinicians should help enroll pregnant patients in the North American Antiepileptic Drug (NAAED) Pregnancy Registry to observe pregnancy outcomes in women exposed to pregabalin during pregnancy and provide information on the effects of in-utero exposure to pregabalin.

Breastfeeding considerations: Because the potential risk outweighs the benefits, breastfeeding or pregabalin should be stopped, especially while nursing newborns or infants.[29]

Older patients: Pregabalin is mainly cleared through the kidneys, putting older patients at higher risk of adverse reactions due to a potential decline in renal function. Therefore, careful dosage selection and regular monitoring of renal function are crucial in this population. According to the AGS beers criteria (2023), reduce the pregabalin dosage if creatinine clearance is less than 60 mL/min.[30]

Pediatric patients: The effectiveness of pregabalin in pediatric patients with focal onset seizures was demonstrated in a study, showing greater seizure reduction compared to placebo in patients who are 1 month to younger than 4 years.[31]

Adverse Effects

Most reported adverse effects caused by pregabalin were mild to moderate intensity, dose-dependent, and occurred within the first 2 weeks of initiating treatment.

  • The most common adverse events were those affecting the central nervous system (CNS). Somnolence and dizziness occurred most frequently and were the most common adverse reactions that led to the discontinuation of pregabalin.[10]
  • The most common adverse reactions reported in premarketing trials for pregabalin, occurring in over 5% of patients and twice the rate compared to placebo, include somnolence, dizziness, blurred vision, difficulty with concentration/attention, dry mouth, edema, and weight gain.[32][33]
  • Weight gain associated with pregabalin is dose-dependent and occurs in up to 14% of patients receiving 600 mg daily.
  • Following rapid or abrupt discontinuation of pregabalin, some patients reported insomnia, nausea, headache, anxiety, nervousness, irritability, hyperhidrosis, and diarrhea.[10]
  • Chronic use of pregabalin can result in physical dependence, and there is a risk of abuse associated with its use, especially in patients on opioid medicines or who have a history of substance abuse.[34]

Drug-Drug Interactions

  • Pregabalin's pharmacokinetics are unlikely to be affected by other agents due to its predominant renal excretion, minimal metabolism, and lack of plasma protein binding. Studies suggest no significant pharmacokinetic interactions between pregabalin and common antiepileptic drugs. Regarding pharmacodynamics, no pharmacokinetic interactions were observed.
  • Coadministration of pregabalin with CNS depressants such as opioids, benzodiazepines, or ethanol is synergistic and should be avoided.[35]

Contraindications

Pregabalin is contraindicated in patients with a known hypersensitivity to pregabalin. Hypersensitivity reactions, including angioedema, have been reported.[36]

Warning and Precautions

  • Pregabalin may cause fetal harm. Counsel patients that there is a potential risk to the fetus.[37]
  • Pregabalin has been detected in breast milk; breastfeeding is not advisable, and an alternative medication is preferred.[29]
  • An analysis of the FAERS (FDA Adverse Event Reporting System) database reveals that pregabalin has been associated with rhabdomyolysis. Patients should report any unexplained muscle symptoms promptly, and treatment should be discontinued if myopathy is suspected or creatine kinase levels are markedly elevated.[38]

Monitoring

Key facts to keep in mind when monitoring:

  • Antiepileptic drugs such as pregabalin may increase the risk of suicidal thoughts or behavior.[39] Patients under treatment with pregabalin should be monitored for symptoms of suicidal ideation or behavior, new or worsening depression, and other changes in behavior or mood.
  • Patients should be monitored for weight gain, edema, respiratory rate, and other adverse events, which could result in issues with treatment adherence with pregabalin.
  • Therapeutic success should be evaluated by periodic evaluation of disease and potential adverse effects.
  • Prescribing cascades, notably involving pregabalin or gabapentin, contribute to polypharmacy in older adults and should be monitored. A study found a significant link between initiating pregabalin or gabapentin and subsequent loop diuretic use, indicating a prescribing cascade.[40]

Toxicity

Signs and Symptoms of Overdose

There is limited information regarding overdose with pregabalin. The highest known accidental overdose of pregabalin during clinical development was 8000 mg; this event was without significant clinical consequences. The most commonly reported adverse events with overdose were reduced consciousness, confusional state, agitation, depression/anxiety, and restlessness in the postmarketing studies. In addition, heart block, seizures, and death have also been reported in some patients taking combination with other CNS depressants.[41]

Management of Overdose

There is no specific antidote for overdose with pregabalin. If required, unabsorbed pregabalin can be eliminated by gastric lavage or emesis. General supportive care should be provided to the patient. Maintain the airway and monitor the patient's vital signs and clinical status. A Certified Poison Control Center (800-222-1222) should be contacted for the latest information on the management of overdose with pregabalin. Pregabalin can be removed by standard hemodialysis procedures, resulting in approximately 50% clearance of pregabalin in 4 hours.

Recommendations

The Extracorporeal Treatments in Poisoning (EXTRIP) suggests against performing extracorporeal treatment (ECTR) in addition to standard care alone for pregabalin/gabapentin poisoning in normal kidney function. However, if decreased kidney function and coma requiring mechanical ventilation are present, the workgroup suggests performing extracorporeal treatment in addition to standard care (weak recommendation, very low quality of evidence).[42]

Enhancing Healthcare Team Outcomes

Pregabalin is commonly used to manage pain disorders and as adjunctive treatment for partial-onset seizures. While the drug is relatively safe, physicians, pharmacists, nurse practitioners, and physician assistants must regularly monitor the patient. Pregabalin is known to cause depression and suicidal thoughts, so a mental assessment is advisable at each visit. Pregabalin should not be prescribed for musculoskeletal pain. Patients should be educated about the other adverse effects and told not to drive when taking the drug or combine it with other antiseizure medications or alcohol. Pharmacists should perform medication reconciliation and watch for potential drug interactions. Nurses should verify the dose before administering and report any concerns to clinicians. Before altering the treatment plan, consultation with a neurologist, psychiatrist, or pain management specialist is beneficial.[5] The collaborative approach of all interprofessional healthcare team members can result in higher treatment success and improve patient outcomes with pregabalin therapy.

References

[1]

Tong C, Zhengyao Z, Mei L, Dongpo S, Qian H, Fengqun M. Pregabalin and Gabapentin in Patients with Spinal Cord Injury-Related Neuropathic Pain: A Network Meta-Analysis. Pain and therapy. 2021 Dec:10(2):1497-1509. doi: 10.1007/s40122-021-00302-8. Epub 2021 Sep 7     [PubMed PMID: 34491542]

Level 1 (high-level) evidence

[2]

Bragg S, Marrison ST, Haley S. Diabetic Peripheral Neuropathy: Prevention and Treatment. American family physician. 2024 Mar:109(3):226-232     [PubMed PMID: 38574212]

[3]

Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgraduate medicine. 2011 Sep:123(5):134-42. doi: 10.3810/pgm.2011.09.2469. Epub     [PubMed PMID: 21904096]

[4]

French J, Kwan P, Fakhoury T, Pitman V, DuBrava S, Knapp L, Yurkewicz L. Pregabalin monotherapy in patients with partial-onset seizures: a historical-controlled trial. Neurology. 2014 Feb 18:82(7):590-7. doi: 10.1212/WNL.0000000000000119. Epub 2014 Jan 10     [PubMed PMID: 24415567]

[5]

Bidari A, Moazen-Zadeh E, Ghavidel-Parsa B, Rahmani S, Hosseini S, Hassankhani A. Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences. 2019 Jun:27(1):149-158. doi: 10.1007/s40199-019-00257-4. Epub 2019 Mar 14     [PubMed PMID: 30877484]

Level 1 (high-level) evidence

[6]

Macfarlane GJ, Kronisch C, Dean LE, Atzeni F, Häuser W, Fluß E, Choy E, Kosek E, Amris K, Branco J, Dincer F, Leino-Arjas P, Longley K, McCarthy GM, Makri S, Perrot S, Sarzi-Puttini P, Taylor A, Jones GT. EULAR revised recommendations for the management of fibromyalgia. Annals of the rheumatic diseases. 2017 Feb:76(2):318-328. doi: 10.1136/annrheumdis-2016-209724. Epub 2016 Jul 4     [PubMed PMID: 27377815]

[7]

Hong JSW, Atkinson LZ, Al-Juffali N, Awad A, Geddes JR, Tunbridge EM, Harrison PJ, Cipriani A. Gabapentin and pregabalin in bipolar disorder, anxiety states, and insomnia: Systematic review, meta-analysis, and rationale. Molecular psychiatry. 2022 Mar:27(3):1339-1349. doi: 10.1038/s41380-021-01386-6. Epub 2021 Nov 24     [PubMed PMID: 34819636]

Level 1 (high-level) evidence

[8]

Kawalec P, Cierniak A, Pilc A, Nowak G. Pregabalin for the treatment of social anxiety disorder. Expert opinion on investigational drugs. 2015 Apr:24(4):585-94. doi: 10.1517/13543784.2014.979283. Epub 2014 Oct 31     [PubMed PMID: 25361817]

Level 3 (low-level) evidence

[9]

Di Iorio G, Matarazzo I, Di Tizio L, Martinotti G. Treatment-resistant insomnia treated with pregabalin. European review for medical and pharmacological sciences. 2013 Jun:17(11):1552-4     [PubMed PMID: 23771546]

[10]

Derry S, Bell RF, Straube S, Wiffen PJ, Aldington D, Moore RA. Pregabalin for neuropathic pain in adults. The Cochrane database of systematic reviews. 2019 Jan 23:1(1):CD007076. doi: 10.1002/14651858.CD007076.pub3. Epub 2019 Jan 23     [PubMed PMID: 30673120]

Level 1 (high-level) evidence

[11]

Boehlke C, Joos L, Coune B, Becker C, Meerpohl JJ, Buroh S, Hercz D, Schwarzer G, Becker G. Pharmacological interventions for pruritus in adult palliative care patients. The Cochrane database of systematic reviews. 2023 Apr 14:4(2023):CD008320. doi: 10.1002/14651858.CD008320.pub4. Epub 2023 Apr 14     [PubMed PMID: 37314034]

Level 1 (high-level) evidence

[12]

Santos-Alonso C, Maldonado Martín M, Sánchez Villanueva R, Álvarez García L, Vaca Gallardo MA, Bajo Rubio MA, Del Peso Gilsanz G, Ossorio González M, Selgas Gutiérrez R. Pruritus in dialysis patients. Review and new perspectives. Nefrologia. 2022 Jan-Feb:42(1):15-21. doi: 10.1016/j.nefroe.2022.02.004. Epub 2022 Feb 15     [PubMed PMID: 36153894]

Level 3 (low-level) evidence

[13]

Adeli SH, Beigi AM, Ahmadpour S, Habibi MA, Pashaei MR, Sharifipour E, Shakeri M, Asghari A. Effects of Pregabalin as a Neural Pathway Inhibitor for the Treatment of Resistant Subacute and Chronic Cough: A Pilot Clinical Trials Study. Reviews on recent clinical trials. 2023:18(4):269-274. doi: 10.2174/0115748871262516230919070559. Epub     [PubMed PMID: 37888808]

Level 3 (low-level) evidence

[14]

Bae H, Cho YW, Kim KT, Allen RP, Earley CJ. The Safety and Efficacy of Pregabalin Add-on Therapy in Restless Legs Syndrome Patients. Frontiers in neurology. 2021:12():786408. doi: 10.3389/fneur.2021.786408. Epub 2021 Nov 29     [PubMed PMID: 34912291]

[15]

Pellitteri G, Versace S, Merlino G, Nilo A, Gigli GL, Valente M. A comprehensive update on the ADMET considerations for α2δ calcium channel ligand medications for treating restless legs syndrome. Expert opinion on drug metabolism & toxicology. 2024 Mar:20(3):133-142. doi: 10.1080/17425255.2024.2329738. Epub 2024 Mar 15     [PubMed PMID: 38482850]

Level 3 (low-level) evidence

[16]

Harden RN, McCabe CS, Goebel A, Massey M, Suvar T, Grieve S, Bruehl S. Complex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 5th Edition. Pain medicine (Malden, Mass.). 2022 Jun 10:23(Suppl 1):S1-S53. doi: 10.1093/pm/pnac046. Epub     [PubMed PMID: 35687369]

[17]

Parikh SK, Silberstein SD. Current Status of Antiepileptic Drugs as Preventive Migraine Therapy. Current treatment options in neurology. 2019 Mar 18:21(4):16. doi: 10.1007/s11940-019-0558-1. Epub 2019 Mar 18     [PubMed PMID: 30880369]

[18]

Bendtsen L, Zakrzewska JM, Abbott J, Braschinsky M, Di Stefano G, Donnet A, Eide PK, Leal PRL, Maarbjerg S, May A, Nurmikko T, Obermann M, Jensen TS, Cruccu G. European Academy of Neurology guideline on trigeminal neuralgia. European journal of neurology. 2019 Jun:26(6):831-849. doi: 10.1111/ene.13950. Epub 2019 Apr 8     [PubMed PMID: 30860637]

[19]

Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy research. 2007 Feb:73(2):137-50     [PubMed PMID: 17126531]

Level 3 (low-level) evidence

[20]

Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004:45 Suppl 6():13-8     [PubMed PMID: 15315511]

[21]

Keller DA, Bassan A, Amberg A, Burns Naas LA, Chambers J, Cross K, Hall F, Jahnke GD, Luniwal A, Manganelli S, Mestres J, Mihalchik-Burhans AL, Woolley D, Tice RR. In silico approaches in carcinogenicity hazard assessment: case study of pregabalin, a nongenotoxic mouse carcinogen. Frontiers in toxicology. 2023:5():1234498. doi: 10.3389/ftox.2023.1234498. Epub 2023 Nov 13     [PubMed PMID: 38026843]

Level 3 (low-level) evidence

[22]

Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-Forster PK, Sessle BJ, Squire P, Stinson J, Taenzer P, Velly A, Ware MA, Weinberg EL, Williamson OD, Canadian Pain Society. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain research & management. 2014 Nov-Dec:19(6):328-35     [PubMed PMID: 25479151]

Level 3 (low-level) evidence

[23]

Davari M, Amani B, Amani B, Khanijahani A, Akbarzadeh A, Shabestan R. Pregabalin and gabapentin in neuropathic pain management after spinal cord injury: a systematic review and meta-analysis. The Korean journal of pain. 2020 Jan 1:33(1):3-12. doi: 10.3344/kjp.2020.33.1.3. Epub     [PubMed PMID: 31888312]

Level 1 (high-level) evidence

[24]

Vertigan AE, Kapela SL, Ryan NM, Birring SS, McElduff P, Gibson PG. Pregabalin and Speech Pathology Combination Therapy for Refractory Chronic Cough: A Randomized Controlled Trial. Chest. 2016 Mar:149(3):639-48. doi: 10.1378/chest.15-1271. Epub 2016 Jan 12     [PubMed PMID: 26447687]

Level 1 (high-level) evidence

[25]

Baldwin D, Woods R, Lawson R, Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ (Clinical research ed.). 2011 Mar 11:342():d1199. doi: 10.1136/bmj.d1199. Epub 2011 Mar 11     [PubMed PMID: 21398351]

Level 1 (high-level) evidence

[26]

Atış G, Bilir Kaya B. Pregabalin treatment of three cases with brachioradial pruritus. Dermatologic therapy. 2017 Mar:30(2):. doi: 10.1111/dth.12459. Epub 2017 Feb 6     [PubMed PMID: 28168835]

Level 3 (low-level) evidence

[27]

Allen RP, Chen C, Garcia-Borreguero D, Polo O, DuBrava S, Miceli J, Knapp L, Winkelman JW. Comparison of pregabalin with pramipexole for restless legs syndrome. The New England journal of medicine. 2014 Feb 13:370(7):621-31. doi: 10.1056/NEJMoa1303646. Epub     [PubMed PMID: 24521108]

Level 1 (high-level) evidence

[28]

Feltner DE, Liu-Dumaw M, Schweizer E, Bielski R. Efficacy of pregabalin in generalized social anxiety disorder: results of a double-blind, placebo-controlled, fixed-dose study. International clinical psychopharmacology. 2011 Jul:26(4):213-20. doi: 10.1097/YIC.0b013e32834519bd. Epub     [PubMed PMID: 21368587]

Level 1 (high-level) evidence

[29]

. Pregabalin. Drugs and Lactation Database (LactMed®). 2006:():     [PubMed PMID: 30000881]

[30]

By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. 2023 Jul:71(7):2052-2081. doi: 10.1111/jgs.18372. Epub 2023 May 4     [PubMed PMID: 37139824]

[31]

Mann D, Antinew J, Knapp L, Almas M, Liu J, Scavone J, Yang R, Modequillo M, Makedonska I, Ortiz M, Kyrychenko A, Nordli D, Farkas V, Farkas MK, A0081042 study group. Pregabalin adjunctive therapy for focal onset seizures in children 1 month to {4 years of age: A double-blind, placebo-controlled, video-electroencephalographic trial. Epilepsia. 2020 Apr:61(4):617-626. doi: 10.1111/epi.16466. Epub 2020 Mar 18     [PubMed PMID: 32189338]

Level 1 (high-level) evidence

[32]

Preuss CV, Kalava A, King KC. Prescription of Controlled Substances: Benefits and Risks. StatPearls. 2024 Jan:():     [PubMed PMID: 30726003]

[33]

. Drugs for chronic insomnia. The Medical letter on drugs and therapeutics. 2018 Dec 17:60(1562):201-205     [PubMed PMID: 30625122]

Level 3 (low-level) evidence

[34]

Chalabianloo F, Schjøtt J. [Pregabalin and its potential for abuse]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke. 2009 Jan 29:129(3):186-7. doi: 10.4045/tidsskr.08.0047. Epub     [PubMed PMID: 19180163]

[35]

Chen C, Lo-Ciganic WH, Winterstein AG, Tighe P, Wei YJ. Concurrent Use of Prescription Opioids and Gabapentinoids in Older Adults. American journal of preventive medicine. 2022 Apr:62(4):519-528. doi: 10.1016/j.amepre.2021.08.024. Epub 2021 Nov 19     [PubMed PMID: 34802816]

[36]

Ortega-Camarero MA, Avila R, Prados Castaño M, Piñero M, Quiralte J, Cimbollek S. Challenge-based pregabalin induced urticaria and angioedema. A case report. Allergologia et immunopathologia. 2012 Sep-Oct:40(5):323. doi: 10.1016/j.aller.2011.09.012. Epub 2012 Jan 21     [PubMed PMID: 22266144]

Level 3 (low-level) evidence

[37]

Andrade C. Safety of Pregabalin in Pregnancy. The Journal of clinical psychiatry. 2018 Oct 2:79(5):. pii: 18f12568. doi: 10.4088/JCP.18f12568. Epub 2018 Oct 2     [PubMed PMID: 30289631]

[38]

Deng Z, Wang S, Wu C. Rhabdomyolysis associated with newer-generation anti-seizure medications (ASMs): a real-world retrospective and pharmacovigilance study. Frontiers in pharmacology. 2023:14():1197470. doi: 10.3389/fphar.2023.1197470. Epub 2023 Oct 2     [PubMed PMID: 37849732]

Level 2 (mid-level) evidence

[39]

Abrahamsson T, Berge J, Öjehagen A, Håkansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug and alcohol dependence. 2017 May 1:174():58-64. doi: 10.1016/j.drugalcdep.2017.01.013. Epub 2017 Feb 28     [PubMed PMID: 28315808]

[40]

Growdon ME, Jing B, Morris EJ, Deardorff WJ, Boscardin WJ, Byers AL, Boockvar KS, Steinman MA. Which older adults are at highest risk of prescribing cascades? A national study of the gabapentinoid-loop diuretic cascade. Journal of the American Geriatrics Society. 2024 Jun:72(6):1728-1740. doi: 10.1111/jgs.18892. Epub 2024 Mar 28     [PubMed PMID: 38547357]

[41]

Evoy KE, Morrison MD, Saklad SR. Abuse and Misuse of Pregabalin and Gabapentin. Drugs. 2017 Mar:77(4):403-426. doi: 10.1007/s40265-017-0700-x. Epub     [PubMed PMID: 28144823]

[42]

Bouchard J, Yates C, Calello DP, Gosselin S, Roberts DM, Lavergne V, Hoffman RS, Ostermann M, Peng A, Ghannoum M, EXTRIP Workgroup. Extracorporeal Treatment for Gabapentin and Pregabalin Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2022 Jan:79(1):88-104. doi: 10.1053/j.ajkd.2021.06.027. Epub 2021 Nov 17     [PubMed PMID: 34799138]

Level 1 (high-level) evidence